Dow Jones (DJIA) Today: E I Du Pont De Nemours & Company (DD) Leads The Day Higher, Pfizer (PFE) Lags

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer..

The Dow Jones Industrial Average ( ^DJI) is trading down 84.0 points (-0.5%) at 17,844 as of Wednesday, May 6, 2015, 9:36 a.m. ET. During this time, 15.3 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 370.5 million. The NYSE advances/declines ratio sits at 1,239 issues advancing vs. 1,423 declining with 277 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

The Dow component leading the way higher looks to be E I du Pont de Nemours & Company (NYSE: DD), which is sporting a 79-cent gain (+1.1%) bringing the stock to $73.58. Volume for E I du Pont de Nemours & Company currently sits at 153,716 shares traded vs. an average daily trading volume of 5.1 million shares.

E I du Pont de Nemours & Company has a market cap of $67.01 billion and is part of the basic materials sector and chemicals industry. Shares are up 0.1% year-to-date as of Tuesday's close. The stock's dividend yield sits at 2.6%.

E. I. du Pont de Nemours and Company operates as a science and technology based company worldwide. The company's Agriculture segment offers corn hybrid, soybean, canola, sunflower, sorghum, inoculants, seed products, wheat, rice, herbicides, fungicides, and insecticides.

TheStreet Ratings rates E I du Pont de Nemours & Company as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, notable return on equity, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

Holding back the Dow today is Pfizer (NYSE: PFE), which is lagging the broader Dow index with an 18-cent decline (-0.5%) bringing the stock to $33.66. This single loss is lowering the Dow Jones Industrial Average by 1.36 points or roughly accounting for 1.6% of the Dow's overall loss. Volume for Pfizer currently sits at 1.6 million shares traded vs. an average daily trading volume of 28.4 million shares.

Pfizer has a market cap of $210.74 billion and is part of the health care sector and drugs industry. Shares are up 10.2% year-to-date as of Tuesday's close. The stock's dividend yield sits at 3.3%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, growth in earnings per share, expanding profit margins and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE..

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing